Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report
Sign Up to like & getrecommendations! Published in 2022 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2022.2081450
Abstract: Abstract Coronavirus Disease 2019 (COVID-19) is affecting millions of people globally. Several neutralizing monoclonal antibodies have been developed to limit the progression and complications of the disease. These treatments provide immediate and passive immunity. The… read more here.
Keywords: aberrant ventricular; ventricular conduction; fibrillation; bamlanivimab ... See more keywords